Exscientia plc (NASDAQ:EXAI – Get Free Report)’s stock price was up 6.5% during trading on Wednesday . The stock traded as high as $5.48 and last traded at $5.43. Approximately 147,576 shares traded hands during mid-day trading, a decline of 77% from the average daily volume of 629,249 shares. The stock had previously closed at $5.10.
Wall Street Analyst Weigh In
Separately, Morgan Stanley restated an “equal weight” rating and issued a $7.00 target price on shares of Exscientia in a research note on Monday, April 22nd.
Exscientia Stock Performance
The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.30 and a current ratio of 6.30. The stock has a market cap of $649.16 million, a P/E ratio of -4.10 and a beta of 0.84. The firm has a 50 day moving average of $5.02 and a two-hundred day moving average of $5.64.
Exscientia (NASDAQ:EXAI – Get Free Report) last announced its quarterly earnings results on Tuesday, May 21st. The company reported ($0.21) earnings per share (EPS) for the quarter. Exscientia had a negative net margin of 666.80% and a negative return on equity of 34.59%. The firm had revenue of $6.70 million for the quarter. On average, research analysts predict that Exscientia plc will post -1.07 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of EXAI. GAMMA Investing LLC lifted its stake in Exscientia by 112.1% in the first quarter. GAMMA Investing LLC now owns 4,356 shares of the company’s stock valued at $25,000 after buying an additional 2,302 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in Exscientia by 76.8% during the first quarter. China Universal Asset Management Co. Ltd. now owns 9,274 shares of the company’s stock worth $53,000 after acquiring an additional 4,029 shares in the last quarter. Values First Advisors Inc. grew its stake in Exscientia by 10.0% in the fourth quarter. Values First Advisors Inc. now owns 55,958 shares of the company’s stock valued at $359,000 after acquiring an additional 5,090 shares during the period. EntryPoint Capital LLC increased its holdings in shares of Exscientia by 22.8% in the first quarter. EntryPoint Capital LLC now owns 31,171 shares of the company’s stock worth $178,000 after acquiring an additional 5,784 shares in the last quarter. Finally, Exchange Traded Concepts LLC raised its position in shares of Exscientia by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 27,275 shares of the company’s stock worth $175,000 after purchasing an additional 6,916 shares during the period. Institutional investors own 41.58% of the company’s stock.
Exscientia Company Profile
Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company’s lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.